Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection
| dc.contributor.author | Orlowski, Piotr | |
| dc.contributor.author | Tomaszewska, Emilia | |
| dc.contributor.author | Gniadek, Marianna | |
| dc.contributor.author | Baska, Piotr | |
| dc.contributor.author | Nowakowska, Julita | |
| dc.contributor.author | Sokolowska, Justyna | |
| dc.contributor.author | Nowak, Zuzanna | |
| dc.contributor.author | Donten, Mikolaj | |
| dc.contributor.author | Celichowski, Grzegorz | |
| dc.contributor.author | Grobelny, Jaroslaw | |
| dc.contributor.author | Krzyzowska, Malgorzata | |
| dc.date.accessioned | 2016-03-24T11:45:55Z | |
| dc.date.available | 2016-03-24T11:45:55Z | |
| dc.date.issued | 2014 | |
| dc.identifier.uri | http://hdl.handle.net/11089/17531 | |
| dc.description.abstract | The interaction between silver nanoparticles and herpesviruses is attracting great interest due to their antiviral activity and possibility to use as microbicides for oral and anogenital herpes. In this work, we demonstrate that tannic acid modified silver nanoparticles sized 13 nm, 33 nm and 46 nm are capable of reducing HSV-2 infectivity both in vitro and in vivo. The antiviral activity of tannic acid modified silver nanoparticles was size-related, required direct interaction and blocked virus attachment, penetration and further spread. All tested tannic acid modified silver nanoparticles reduced both infection and inflammatory reaction in the mouse model of HSV-2 infection when used at infection or for a post-infection treatment. Smaller-sized nanoparticles induced production of cytokines and chemokines important for anti-viral response. The corresponding control buffers with tannic acid showed inferior antiviral effects in vitro and were ineffective in blocking in vivo infection. Our results show that tannic acid modified silver nanoparticles are good candidates for microbicides used in treatment of herpesvirus infections. | pl_PL |
| dc.description.sponsorship | This work was supported by the Polish National Science Centre grant No. 2011/03/B/NZ6/04878 (for MK) and Centre for Preclinical Research and Technology (CePT) Project No. POIG.02.02.00-14-024/08-0 (for MG and MD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript | pl_PL |
| dc.language.iso | en | pl_PL |
| dc.publisher | PLOS | pl_PL |
| dc.relation.ispartofseries | PLOSone;8 | |
| dc.rights | Uznanie autorstwa 3.0 Polska | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
| dc.title | Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection | pl_PL |
| dc.type | Article | pl_PL |
| dc.page.number | 1-15 | pl_PL |
| dc.contributor.authorAffiliation | Military Institute of Hygiene and Epidemiology, Department of Regenerative Medicine | pl_PL |
| dc.contributor.authorAffiliation | University of Lodz, Faculty of Chemistry | pl_PL |
| dc.contributor.authorAffiliation | University of Warsaw | pl_PL |
| dc.contributor.authorAffiliation | Warsaw University of Life Sciences | pl_PL |
| dc.references | Shukla D, Spear PG (2001) Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 108: 503–510. | pl_PL |
| dc.references | Garner JA (2003) Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv Drug Deliv Rev 55: 1497–1513. | pl_PL |
| dc.references | Akhtar J, Shukla D (2009) Viral entry mechanism: cellular and viral mediators of herpes simplex virus entry. FEBS J 276: 7228–7236. | pl_PL |
| dc.references | Gupta R, Warren T, Wald A (2007) Genital herpes. Lancet 370: 2127–2137. | pl_PL |
| dc.references | Halioua B, Malkin JE (1999) Epidemiology of genital herpes – recent advances. Eur J Dermatol 9: 177–184. | pl_PL |
| dc.references | Kahababaee K, van Ree T (2001) Tannins: classification and definition. Nat Prod Rep 18: 641–649. | pl_PL |
| dc.references | Haslam E (2007) Vegetable tannins - lessons of a plant phytochemical lifetime. Phytochemistry 68: 2713–2721. | pl_PL |
| dc.references | Athar M, Khan WA, Mukhtar H (1989) Effect of dietary tannic acid on epidermal, lung, and forestomach polycyclic aromatic hydrocarbon metabolism and tumorigenicity in Sencar mice. Cancer Res 49: 5784–5788. | pl_PL |
| dc.references | Horikawa K, Mohri T, Tanaka Y, Tokiwa H (1994) Moderate inhibition of mutagenicity and carcinogenicity of benzo[a]pyrene, 1,6-dinitropyrene and 3,9-dinitrofluoranthene by Chinese medicinal herbs. Mutagenesis 9: 523–526. | pl_PL |
| dc.references | Chung KT, Stevens SE Jr, Lin WF, Wei CI (1993) Growth inhibition of selected food-borne bacteria by tannic acid, propyl gallate and related compounds. Appl Microbiol 1: 29–32. | pl_PL |
| dc.references | Fukuchi K, Sakagami H, Okuda T, Hatano T, Tanuma S, et al. (1989) Inhibition of herpes simplex virus infection by tannins and related compounds. Antiviral Res 11: 285–298. | pl_PL |
| dc.references | Scalbert A (1989) Antimicrobial properties of tannins. Phytochemistry 30: 3875–3883. | pl_PL |
| dc.references | Akiyama H, Fujii K, Yamasaki O, Oono T, Iwatsuki K (2001) Antibacterial action of several tannins against Staphylococcus aureus. J Antimicrob Chemother 48: 487–491. | pl_PL |
| dc.references | Nelofer SK, Ahmad A, Hadi SM (2000) Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. Chem Biol Interact 125: 177–189. | pl_PL |
| dc.references | Lin LT, Chen TY, Chung CY, Noyce RS, Gridley TB, et al. (2011) Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol 85: 4386–4398. | pl_PL |
| dc.references | Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, et al. (2005) The bactericidal effect of silver nanoparticles. Nanotechnology 16: 2346–2353. | pl_PL |
| dc.references | Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, et al. (2007) Antimicrobial effects of silver nanoparticles. Nanomedicine 3: 95–101. | pl_PL |
| dc.references | Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, et al. (2008) Antifungal effect of silver nanoparticles on dermatophytes. J Microbiol Biotechnol 18: 148–1484. | pl_PL |
| dc.references | Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, et al. (2005) Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 3: 6. | pl_PL |
| dc.references | Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C (2010) Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 8: 1. | pl_PL |
| dc.references | Lu L, Sun RW, Chen R, Hui CK, Ho CM, et al. (2008) Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 13: 253–262. | pl_PL |
| dc.references | Xiang D, Zheng Y, Duan W, Li X, Yin J, et al. (2013) Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine 8: 4103–4114. | pl_PL |
| dc.references | Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R (2009) Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethanesulfonate. Bioconjug Chem 19: 1497–1502. | pl_PL |
| dc.references | Kleymann G (2005) Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Investig Drugs 14: 135–161. | pl_PL |
| dc.references | Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55: 459–472. | pl_PL |
| dc.references | Levin MJ, Bacon TH, Leary JJ (2004) Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 39: 248–257. | pl_PL |
| dc.references | Wade JC (2006) Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program 2006: 368–374. | pl_PL |
| dc.references | Tobian AA, Quinn TC (2009) Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 4: 294–299. | pl_PL |
| dc.references | Orlowski P, Krzyzowska M, Zdanowski R, Winnicka A, Nowakowska J, et al. (2013) Assessment of in vitro cellular responses of monocytes and keratinocytes to tannic acid modified silver nanoparticles. Toxicol In vitro 27: 1798–1808. | pl_PL |
| dc.references | Duff R, Rapp F (1971) Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nat New Biol 233: 48–50. | pl_PL |
| dc.references | Krzyzowska M, Shestakov A, Eriksson E, Chiodi F (2011) Role of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection. Cell Death Dis 2: 1–12. | pl_PL |
| dc.references | Gunalp A (1965) Growth and cytopathic effect of rubella virus in a line of green monkey kidney cells. Proc Soc Exp Biol Med 118: 185–190. | pl_PL |
| dc.references | Kulesz-Martin M, Yoshida MA, Prestine L, Yuspa SH, Bertram JS (1985) Mouse cell clones for improved quantitation of carcinogen-induced altered differentiation. Carcinogenesis 6: 1245–1254. | pl_PL |
| dc.references | Varghese M1, Gorsevski P, Cayer ML, Boudreau NS, Heckman CA (2012) Unraveling the determinants of protrusion formation. Int J Cell Biol 2012: 402916. | pl_PL |
| dc.references | Namvar L, Olofsson S, Bergstrom T, Lindh M (2005) Detection and typing of herpes simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J Clin Microbiol 43: 2058–2064. | pl_PL |
| dc.references | Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, et al. (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70: 369–380. | pl_PL |
| dc.references | Krzyzowska M, Baska P, Grochowska A, Orlowski P, Nowak Z, et al. (2014) Fas/FasL pathway participates in resolution of mucosal inflammatory response early during HSV-2 infection. Immunobiology 219: 64–77. | pl_PL |
| dc.references | Galvin SR, Cohen MS (2004) The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2: 33–42. | pl_PL |
| dc.references | Mohammed Fayaz A, Ao Z, Girilal M, Chen L, Xiao X, et al. (2012) Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomedicine 7: 5007–5018. | pl_PL |
| dc.references | Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, Rodriguez-Padilla C (2010) PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 8: 15. | pl_PL |
| dc.references | Baram-Pinto D, Shukla S, Gedanken A, Sarid R (2010) Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small 6: 1044–1050. | pl_PL |
| dc.references | Lin LT1, Chen TY, Lin SC, Chung CY, Lin TC, et al. (2013) Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol 13: 187. | pl_PL |
| dc.references | de Lima R, Seabra AB, Durán N (2012) Silver nanoparticles: a brief review of cytotoxicity and genotoxicity of chemically and biogenically synthesized nanoparticles. J Appl Toxicol 32: 867–879. | pl_PL |
| dc.references | Grünewald K, Desai P, Winkler DC, Heymann JB, Belnap DM, et al. (2003) Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science 302: 1396–1398. | pl_PL |
| dc.references | Trefry JC, Wooley DP (2013) Silver nanoparticles inhibit vaccinia virus infection by preventing viral entry through a macropinocytosis-dependent mechanism. J Biomed Nanotechnol 9: 1624–1635. | pl_PL |
| dc.references | Gaikwad S, Ingle A, Gade A, Rai M, Falanga A, et al. (2013) Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. Int J Nanomedicine 8: 4303–4314. | pl_PL |
| dc.references | Pal S, Tak YK, Song JM (2007) Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 73: 1712–1720. | pl_PL |
| dc.references | Yen HJ, Hsu SH, Tsai CL (2009) Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 5: 1553–1561. | pl_PL |
| dc.references | Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, et al. (2010) A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 40: 328–346. | pl_PL |
| dc.references | Liu W, Wu Y, Wang C, Li HC, Wang T, et al. (2010) Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology 4: 319–330. | pl_PL |
| dc.references | Samberg ME, Oldenburg SJ, Monteiro-Riviere NA (2010) Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ Health Perspect 118: 407–413. | pl_PL |
| dc.references | Milligan GN (1999) Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J Virol 73: 6380–6386. | pl_PL |
| dc.references | Wong KK, Cheung SO, Huang L, Niu J, Tao C, et al. (2009) Further evidence of the anti-inflammatory effects of silver nanoparticles. Chem Med Chem 4: 1129–1135. | pl_PL |
| dc.references | Yilma AN, Singh SR Dixit S, Dennis VA (2013) Anti-inflammatory effects of silver-polyvinyl pyrrolidone (Ag-PVP) nanoparticles in mouse macrophages infected with live Chlamydia trachomatis. Int J Nanomedicine 8: 2421–2432. | pl_PL |
| dc.references | Liu H, Yang D, Yang H, Zhang H, Zhang W, et al. (2013) Comparative study of respiratory tract immune toxicity induced by three sterilisation nanoparticles: Silver, zinc oxide and titanium dioxide. J Hazard Mater 248–249: 478–486. | pl_PL |
| dc.references | Cumberbatch M, Dearman RJ, Kimber I (1997) Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration. Adv Exp Med Biol 92: 125–128. | pl_PL |
| dc.references | Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, et al. (2013) Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production. J Invest Dermatol 133: 2170–2179. | pl_PL |
| dc.references | Iijima N, Mattei LM, Iwasaki A (2011) Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 108: 284–289. | pl_PL |
| dc.references | Thapa M, Carr DJ (2008) Chemokines and chemokine receptors critical to host resistance following genital herpes simplex virus type 2 (HSV-2) infection. Open Immunol J 1: 33–41. | pl_PL |
| dc.references | Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisakk P, et al. (2005) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129: 212–223. | pl_PL |
| dc.references | Campbell SJ, Perry VH, Pitossi FJ, Butchart AG, Chertoff M, et al. (2005) Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am J Pathol 166: 1487–1497. | pl_PL |
| dc.references | Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339–342. | pl_PL |
| dc.references | Paludan SR (2001) Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J Virol 75: 8008–8015. | pl_PL |
| dc.references | Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8 (+) T lymphocyte mobilization to virus-infected tissue requires CD4 (+) T-cell help. Nature 462: 510–513. | pl_PL |
| dc.references | Lund JM, Hsing L, Pham TT, Rudensky AY (2008) Coordination of early protective immunity to viral infection by regulatory T cells. Science 320: 1220–1224. | pl_PL |
| dc.contributor.authorEmail | krzyzowskam@yahoo.com | pl_PL |
| dc.identifier.doi | 10.1371/journal.pone.0104113 | |
| dc.relation.volume | 9 | pl_PL |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Uznanie autorstwa 3.0 Polska